Mochida and Fuji submit first biosimilar G-CSF in Japan
This article was originally published in Scrip
Executive Summary
Mochida and co-development partner Fuji Pharma have filed for the approval in Japan of a biosimilar recombinant granulocyte colony-stimulating factor (G-CSF) product for the treatment of neutropenia associated with cancer chemotherapy.